Search alternatives:
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
larger decrease » marked decrease (Expand Search)
mean decrease » a decrease (Expand Search)
Showing 12,321 - 12,340 results of 51,875 for search '(( a ((mean decrease) OR (linear decrease)) ) OR ( a ((largest decrease) OR (larger decrease)) ))', query time: 0.74s Refine Results
  1. 12321
    Vomit-free days up to day 10.

    Vomit-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  2. 12322
    Symptoms free-days up to day 10.

    Symptoms free-days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  3. 12323
    Respiratory symptoms-free days up to day 10.

    Respiratory symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  4. 12324
    Other symptoms-free days up to day 10.

    Other symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  5. 12325
    Diarrhea-free days up to day 10.

    Diarrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  6. 12326
    Gastrointestinal symptoms-free days up to day 10.

    Gastrointestinal symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  7. 12327
    Nausea-free days up to day 10.

    Nausea-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  8. 12328
    Flow of patients in Halos trial.

    Flow of patients in Halos trial. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  9. 12329
    Cough-free days up to day 10.

    Cough-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  10. 12330
    Dyspnea-free days up to day 10.

    Dyspnea-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  11. 12331
    Raincloud plots with median, quartile, density and individual data points for CV%’s of the DJ metrics across the three time-points analyzed.

    Raincloud plots with median, quartile, density and individual data points for CV%’s of the DJ metrics across the three time-points analyzed. by Nicolas M. Philipp (13272198)

    Published 2023
    Save to List
    Saved in:
  12. 12332
    Biological processes showing up-regulation or down-regulation of genes in activated neutrophils.

    Biological processes showing up-regulation or down-regulation of genes in activated neutrophils. by Jeffrey A. Ericson (639257)

    Published 2014
    “…<p>(<b>A–H</b>). Heat maps show mean expression in neutrophils from blood (BL), synovial fluid (SF), or peritonitis induced by uric acid (UA) or thioglycollate (TG). …”
    Save to List
    Saved in:
  13. 12333
    Thymol and its combination with classical anthelmintics.

    Thymol and its combination with classical anthelmintics. by Guillermina Hernando (553795)

    Published 2019
    Save to List
    Saved in:
  14. 12334
    <i>NAB3</i> reduces the level of <i>IMD2</i> CUT terminator readthrough product from a reporter and native <i>IMD2</i> CUT and readthrough RNA, but <i>NAB3</i> does not significantly affect the termination of native <i>IMD2</i> CUT in <i>air1/2</i> cells.

    <i>NAB3</i> reduces the level of <i>IMD2</i> CUT terminator readthrough product from a reporter and native <i>IMD2</i> CUT and readthrough RNA, but <i>NAB3</i> does not significant... by Milo B. Fasken (659389)

    Published 2015
    “…<i>nab3-R331A</i>, <i>nab3-F333A</i>, and <i>nab3-S399A</i> RRM mutants do not decrease level of GFP from pREF-GFP reporter in <i>air1/2</i> cells. …”
    Save to List
    Saved in:
  15. 12335
    Pre-incubation of SB105-A10 either with HIV-1<sub>IIIb</sub> or HIV-1<sub>ada</sub> strains inhibits the viral infectivity in dilution assay.

    Pre-incubation of SB105-A10 either with HIV-1<sub>IIIb</sub> or HIV-1<sub>ada</sub> strains inhibits the viral infectivity in dilution assay. by Isabella Bon (467395)

    Published 2013
    “…<p>HIV-1 strains were incubated for 1 hour at 37°C with SB105-A10 (20 µg/ml; 4.2 µM). Following this incubation the samples were diluted 50-fold to reduce dendrimer concentrations to a level below that at which SB105-A10 significantly inhibits HIV replication and challenged with activated PBMCs. …”
    Save to List
    Saved in:
  16. 12336
    Gravitational Fingering Due to Density Increase by Mixing at a Vertical Displacing Front in Porous Media

    Gravitational Fingering Due to Density Increase by Mixing at a Vertical Displacing Front in Porous Media by Lei Wang (6656)

    Published 2017
    “…In the fingers, the local NaI concentration decreased linearly and the initial interface traveled downward as a result of the enhanced interaction of the fingers during the injection process. …”
    Save to List
    Saved in:
  17. 12337
    Gravitational Fingering Due to Density Increase by Mixing at a Vertical Displacing Front in Porous Media

    Gravitational Fingering Due to Density Increase by Mixing at a Vertical Displacing Front in Porous Media by Lei Wang (6656)

    Published 2017
    “…In the fingers, the local NaI concentration decreased linearly and the initial interface traveled downward as a result of the enhanced interaction of the fingers during the injection process. …”
    Save to List
    Saved in:
  18. 12338
    Gravitational Fingering Due to Density Increase by Mixing at a Vertical Displacing Front in Porous Media

    Gravitational Fingering Due to Density Increase by Mixing at a Vertical Displacing Front in Porous Media by Lei Wang (6656)

    Published 2017
    “…In the fingers, the local NaI concentration decreased linearly and the initial interface traveled downward as a result of the enhanced interaction of the fingers during the injection process. …”
    Save to List
    Saved in:
  19. 12339
    Influences of parabolic flight on activity of wrist and trunk activities.

    Influences of parabolic flight on activity of wrist and trunk activities. by Peiliang Wang (753153)

    Published 2015
    Save to List
    Saved in:
  20. 12340
    Cumulative and ruptured oocysts.

    Cumulative and ruptured oocysts. by Lauren M. Childs (593877)

    Published 2017
    Save to List
    Saved in:

Search Tools: